Canadian molecular diagnostics firm Qvella is developing a sepsis diagnostic that uses differences in surface charge and mobility to pluck sepsis-causing pathogens from blood samples. The firm announced yesterday that it had raised $20 million in Series A financing to further develop its products and expand its team.

Read more